Table 2.
Accuracy | Specificity | Sensitivity | Indication | Limitation | |
MDCT | 40–50% | 60–90% | 50–90% | Basic staging study | Lacks accuracy in neo- adjuvant and follow – up setting |
MRI | 70–80% | 70–90% | 55–75% | Similar benefits to MDCTNewer modalities (DWI sequence, newer contrast agents) have the potential to increase accuracy | Not widely availableSome of its characteristics are still under investigationExpensive |
EUS | 50–80% | 80–90% | 70–80% | Accurate for regional lymph nodesAddition of FNA offers tissue confirmation | Inadequate for distal metastasesOperator – dependentInherent limitations in certain anatomic areas |
PET | 30–40% | 40–50% | >90% | High sensitivityDetects distant metastases with higher sensitivity than other modalities | Inadequate for loco – regional diseaseHigh rate of false positive resultsExpensiveNot widely available |